Do cannabinoids reduce multiple sclerosis-related spasticity?

Neurologist

Volumn 15, Issue 6, 2009, Pages 369-371

  Thaera, Greg M ^a   Wellik, Kay E ^a   Carter, Jonathan L ^a   Demaerschalk, Bart M ^a   Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cannabinoids; Cannabis; Critically Appraised topic; Evidence based medicine; Multiple sclerosis; Spasticity

Indexed keywords

CANNABINOID; DRONABINOL;

ARTICLE; CLINICAL TRIAL; DEPRESSION; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; IRRITABILITY; MULTIPLE SCLEROSIS; MUSCLE SPASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SLEEP; SPASTICITY;

ADULT; CANNABINOIDS; HUMANS; MALE; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN;

EID: 73349092384     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181bf5572     Document Type: Article

References (10)

1. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol. 2003;2:291-298.
2. Clark AJ, Ware MA, Yazer E, et al. Patters of cannabis use among patients with multiple sclerosis. Neurology. 2004;62:2098-2100.
3. Chong MS, Wolff K, Wise K, et al. Cannabis use in patients with multiple sclerosis. Mult Scler. 2006;12:646-651.
4. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540-542.
5. Zajicek JP, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (the CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003; 362:1517-1526.
6. Collin C, Davies P, Mutiboko IK, et al, for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14:290-296.
7. Hinderer SR, Gupta S. Functional outcome measures to assess interventions for spasticity. Arch Phys Med Rehabil. 1996;77:1083-1089.
8. Metz L, Page S. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet. 2003;362:1513.
9. Wingerchuk D. Cannabis for medical purposes: cultivating science, weeding out the fiction. Lancet. 2004;364:315.
10. Killestein J, Polman C. The therapeutic value of cannabinoids in MS: real or imaginary? Mult Scler. 2004;10:339-340.